WallStreetZenWallStreetZen

NASDAQ: AMLX
Amylyx Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for AMLX

Based on 5 analysts offering 12 month price targets for Amylyx Pharmaceuticals Inc

Min Forecast
$39.00+48.06%
Avg Forecast
$49.00+86.03%
Max Forecast
$57.00+116.4%

Should I buy or sell AMLX stock?

Based on 5 analysts offering ratings for Amylyx Pharmaceuticals Inc.

Strong Buy
Strong Buy
2 analysts 40%
Buy
3 analysts 60%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although AMLX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates AMLX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their AMLX stock forecasts and price targets.

AMLX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-10-15Find Out Why
lockedlocked$00.00+00.00%2026-08-27Find Out Why
lockedlocked$00.00+00.00%2026-08-19
lockedlocked$00.00+00.00%2026-08-19
lockedlocked$00.00+00.00%2026-08-18

1 of 1

Forecast return on equity

Is AMLX forecast to generate an efficient return?

Company
99.32%
Industry
25.06%
Market
177.77%
AMLX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AMLX forecast to generate an efficient return on assets?

Company
89.78%
Industry
23.99%
AMLX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AMLX earnings per share forecast

What is AMLX's earnings per share in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
-$1.55
Avg 2 year Forecast
-$1.42
Avg 3 year Forecast
-$0.42

AMLX revenue forecast

What is AMLX's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$68.4M
Avg 3 year Forecast
$185.5M

AMLX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AMLX$26.34$49.00+86.03%Strong Buy
VKTX$25.17$97.83+288.69%Strong Buy
TARS$68.07$100.86+48.17%Strong Buy
RCUS$22.12$37.13+67.83%Buy
DNLI$17.61$33.25+88.81%Strong Buy
View Top Biotech Stocks

Amylyx Pharmaceuticals Stock Forecast FAQ

Is Amylyx Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: AMLX) stock is to Strong Buy AMLX stock.

Out of 5 analysts, 2 (40%) are recommending AMLX as a Strong Buy, 3 (60%) are recommending AMLX as a Buy, 0 (0%) are recommending AMLX as a Hold, 0 (0%) are recommending AMLX as a Sell, and 0 (0%) are recommending AMLX as a Strong Sell.

If you're new to stock investing, here's how to buy Amylyx Pharmaceuticals stock.

What is AMLX's earnings growth forecast for 2026-2028?

(NASDAQ: AMLX) Amylyx Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.8%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.78%.

Amylyx Pharmaceuticals's earnings in 2026 is -$152,092,000.On average, 12 Wall Street analysts forecast AMLX's earnings for 2026 to be -$172,360,313, with the lowest AMLX earnings forecast at -$174,711,339, and the highest AMLX earnings forecast at -$159,936,643. On average, 12 Wall Street analysts forecast AMLX's earnings for 2027 to be -$157,908,744, with the lowest AMLX earnings forecast at -$185,407,952, and the highest AMLX earnings forecast at -$129,863,562.

In 2028, AMLX is forecast to generate -$46,663,973 in earnings, with the lowest earnings forecast at -$132,671,423 and the highest earnings forecast at $44,457,796.

What is AMLX's revenue growth forecast for 2026-2028?

(NASDAQ: AMLX) Amylyx Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.13%.

Amylyx Pharmaceuticals's revenue in 2026 is $0.On average, 10 Wall Street analysts forecast AMLX's revenue for 2026 to be $0, with the lowest AMLX revenue forecast at $0, and the highest AMLX revenue forecast at $0. On average, 12 Wall Street analysts forecast AMLX's revenue for 2027 to be $7,621,559,329, with the lowest AMLX revenue forecast at $1,064,424,378, and the highest AMLX revenue forecast at $33,998,514,636.

In 2028, AMLX is forecast to generate $20,664,518,482 in revenue, with the lowest revenue forecast at $6,261,975,298 and the highest revenue forecast at $43,662,235,589.

What is AMLX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: AMLX) forecast ROA is 89.78%, which is higher than the forecast US Biotechnology industry average of 23.99%.

What is AMLX's Price Target?

According to 5 Wall Street analysts that have issued a 1 year AMLX price target, the average AMLX price target is $49.00, with the highest AMLX stock price forecast at $57.00 and the lowest AMLX stock price forecast at $39.00.

On average, Wall Street analysts predict that Amylyx Pharmaceuticals's share price could reach $49.00 by Oct 15, 2027. The average Amylyx Pharmaceuticals stock price prediction forecasts a potential upside of 86.03% from the current AMLX share price of $26.34.

What is AMLX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: AMLX) Amylyx Pharmaceuticals's current Earnings Per Share (EPS) is -$1.41. On average, analysts forecast that AMLX's EPS will be -$1.55 for 2026, with the lowest EPS forecast at -$1.57, and the highest EPS forecast at -$1.44. On average, analysts forecast that AMLX's EPS will be -$1.42 for 2027, with the lowest EPS forecast at -$1.66, and the highest EPS forecast at -$1.17. In 2028, AMLX's EPS is forecast to hit -$0.42 (min: -$1.19, max: $0.40).

What is AMLX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: AMLX) forecast ROE is 99.32%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.